FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Ranbaxy Seeks Help from Giuliani

[ Price : $8.95]

Ranbaxy hires former GOP presidential hopeful Rudy Giuliani to review FDA compliance issues from recent Warning Letters and an Imp...

CDRH Presentation Incorrect on Enforcement

[ Price : $8.95]

CDRH corrects an erroneous enforcement statistic presented by director Dan Schultz at a RAPS session in Boston 9/15.

Carcinogenicity Study Dose Selection Guidance

[ Price : $8.95]

FDA issues an ICH guidance to help sponsors select appropriate doses for rodent carcinogenicity studies.

Further Study Needed for Gilead CF Drug

[ Price : $8.95]

FDA says Gilead Sciences must conduct another clinical trial on its investigation cystic fibrosis drug aztreonam lysine.

Approval Sought for New Azor Indication

[ Price : $8.95]

Daiichi Sankyo files an sNDA for its Azor as initial hypertension therapy in patients likely to need multiple drugs to meet blood ...

Senate Committee Looks at Device Ads

[ Price : $8.95]

CDRH director Daniel Schultz tells a Senate committee there are significant regulatory differences and requirements between DTC ad...

FDA OKs Gore Endoprosthesis in Iliac Artery

[ Price : $8.95]

FDA approves W.L. Gores Gore Viabahn endoprosthesis for use in patients with symptomatic peripheral arterial disease in iliac arte...

Animal Health Pharma sNADA for Horses OKd

[ Price : $8.95]

Federal Register Final rule: FDA approves an Animal Health Pharmaceuticals supplemental NADA for revised labeling for an oral susp...

Date Confirmed on Baseline Reporting

[ Price : $8.95]

Federal Register Direct final rule: FDA confirms the effective date for a Federal Register final rule removing the requirement for...

One in Eight Approval Actions Require a REMS: Axelrad

[ Price : $8.95]

CDER associate director for policy Jane Axelrad tells an industry conference that about one in eight approval actions taken since ...